Last updated on July 2018

Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL)

Brief description of study

The trial will enroll 194 previously untreated DLBCL patients over 20 months, with the objective to send to the local investigator an extensive molecular tumor characterization by D38 in at least 80% of enrolled patients.

The feasibility and efficiency will be demonstrated by deploying and operating a nation-wide network of dedicated multidisciplinary platforms.

Clinical Study Identifier: NCT03104478

Contact Investigators or Research Sites near you

Start Over

Nicolas DAGUINDAU, Doctor

Ch Annecy Genevois
Pringy, France
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.